What is the expected growth forecast for the Transient Receptor Potential Cation Channel Subfamily V Member 1 market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033.

What are the major challenges faced by the Transient Receptor Potential Cation Channel Subfamily V Member 1 market?

High development costs and regulatory hurdles are major challenges.

What is the current regulatory landscape of the Transient Receptor Potential Cation Channel Subfamily V Member 1 market?

The market is regulated by authorities such as FDA and EMA.

Transient Receptor Potential Cation Channel Subfamily V Member 1 Growth Analysis & Future Outlook 2033

Transient Receptor Potential Cation Channel Subfamily V Member 1 by Application (Ophthalmology, Immunology, Muscle Spasm, Pruritus, Abdominal Pain, Others), by Types (CMX-020, CA-016, DD-04107, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 117

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 117

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Transient Receptor Potential Cation Channel Subfamily V Member 1 Market Size | CAGR 15.2 Forecast 2033

Transient Receptor Potential Cation Channel Subfamily V Member 1 Growth Analysis & Future Outlook 2033

🏭 Healthcare🌍 Global

Pages: 117

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 117

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Transient Receptor Potential Cation Channel Subfamily V Member 1 Market Overview

The Transient Receptor Potential Cation Channel Subfamily V Member 1 market, also known as TRPV1, is a crucial segment in the pharmaceutical and biotechnology industries. As a key area of focus, the Transient Receptor Potential Cation Channel Subfamily V Member 1 market size is expected to reach $1.4 billion by 2026, with a growth outlook that is primarily driven by the increasing demand for pain management therapies. The market forecast suggests a compound annual growth rate (CAGR) of 8.5% from 2026 to 2033, with the global industry expansion being fueled by advancements in research and development. The scope of this market encompasses various therapeutic applications, including pain management, inflammation, and respiratory disorders, with a focus on small molecule therapies and biologics.

Loading chart…

The current Transient Receptor Potential Cation Channel Subfamily V Member 1 market is characterized by several key forces, including technology shifts towards more targeted and personalized therapies, regulatory pressures to ensure safety and efficacy, and consumer behavior driven by increasing awareness of available treatment options. The largest region in terms of market share is North America, while the fastest-growing region is anticipated to be the Asia-Pacific. Overall, the Transient Receptor Potential Cation Channel Subfamily V Member 1 market is poised for significant growth, driven by the increasing demand for innovative therapies and the expanding research landscape.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.72 billion
Growth rate	CAGR of 15.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Amgen Inc.; Amorepacific Corp; BCN Peptides SA; Centrexion Therapeutics Corp; Daewoong Pharmaceutical Co Ltd; DoNatur GmbH; Flex Pharma Inc.; Grunenthal GmbH; Kyowa Hakko Kirin Co Ltd; Medifron DBT Co Ltd; Neurim Pharmaceuticals Ltd; Pila Pharma AB; Sylantis SAU; Toray Industries Inc.; Vitality Biopharma Inc
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Transient Receptor Potential Cation Channel Subfamily V Member 1 market is experiencing significant fluctuations due to various factors. The growth drivers, restraints, opportunities, and challenges in this market are crucial for understanding its current and future landscape.

Growth Drivers2 items

Increasing research and development activities in the pharmaceutical industry are driving the Transient Receptor Potential Cation Channel Subfamily V Member 1 market size, with a focus on developing new treatments for various diseases.

Advancements in technology, such as gene editing and gene therapy, are expected to fuel the growth forecast of the Transient Receptor Potential Cation Channel Subfamily V Member 1 market in the coming years.

Restraints2 items

The high cost associated with research and development activities in the Transient Receptor Potential Cation Channel Subfamily V Member 1 market is a significant restraint, as it can be a barrier to entry for new companies and limit the growth of existing ones.

Stringent regulatory requirements and the need for extensive clinical trials are also limiting the growth of the Transient Receptor Potential Cation Channel Subfamily V Member 1 market size, as they can be time-consuming and costly.

Opportunities2 items

The increasing prevalence of diseases, such as cancer and neurological disorders, is creating opportunities for the Transient Receptor Potential Cation Channel Subfamily V Member 1 market to grow, as there is a need for new and effective treatments.

The rising demand for personalized medicine is also expected to drive the growth forecast of the Transient Receptor Potential Cation Channel Subfamily V Member 1 market, as companies focus on developing targeted therapies.

Challenges2 items

The Transient Receptor Potential Cation Channel Subfamily V Member 1 market is facing challenges due to the complexity of the disease biology, which can make it difficult to develop effective treatments.

The intense competition in the market, particularly from established companies, is also a challenge, as it can limit the growth opportunities for new entrants and make it difficult for them to gain market share.

Market Segmentation

Loading chart…

The Application segment of the Transient Receptor Potential Cation Channel Subfamily V Member 1 market refers to the various uses of TRPV1 in different fields. This includes pain management, inflammatory disorders, and other therapeutic areas. The application segment is a crucial part of the Transient Receptor Potential Cation Channel Subfamily V Member 1 segmentation, as it helps to identify the specific areas where TRPV1 is being utilized, thereby contributing to the overall market size.

The Types segment of the Transient Receptor Potential Cation Channel Subfamily V Member 1 market encompasses the different subtypes of TRPV1, including [object Object] and [object Object]. Understanding the types of TRPV1 is essential for market taxonomy, as it allows for a more precise analysis of the market and its various components. By examining the different subtypes, researchers can gain insights into the specific characteristics and functions of each type, ultimately contributing to the development of new treatments and therapies.

Transient Receptor Potential Cation Channel Subfamily V Member 1 Segmentation Breakdown12 items

Application

Ophthalmology

Immunology

Muscle Spasm

Pruritus

Abdominal Pain

Others

Types

CMX-020

CA-016

DD-04107

Others

Regional Insights

Loading chart…

The Transient Receptor Potential Cation Channel Subfamily V Member 1 market is expected to witness significant growth globally, with the Asia Pacific region being the largest and fastest-growing. Key drivers in North America include increasing adoption of advanced technologies, favorable policies, and high investments in research and development. In Europe, drivers such as growing demographics with specific conditions, improving infrastructure, and a mature ecosystem contribute to the growth of the Transient Receptor Potential Cation Channel Subfamily V Member 1 market.

In Asia Pacific, factors like large demographics, increasing adoption of innovative treatments, and rising investments in healthcare infrastructure propel the market growth. Latin America and Middle East & Africa are also expected to contribute to the regional forecast, driven by expanding infrastructure, growing awareness, and improving ecosystem maturity. The Transient Receptor Potential Cation Channel Subfamily V Member 1 market growth is anticipated to be significant in these regions, driven by the aforementioned key factors.

Competitive Landscape

The Transient Receptor Potential Cation Channel Subfamily V Member 1 market is moderately consolidated, with a mix of global players and local companies competing on pricing, distribution, and product innovation. The Transient Receptor Potential Cation Channel Subfamily V Member 1 competitive landscape is characterized by key competitive levers such as certifications and regulatory approvals, which play a crucial role in determining market share. Global players are focusing on expanding their product portfolio, while local companies are concentrating on regional expansion and partnerships.

Companies in this market are adopting various strategies to differentiate themselves, including M&A, partnerships, and product launches. However, they face challenges such as margin pressure, compliance costs, and commoditization. To stay competitive, companies are focusing on technology, service model, and channel strength to differentiate themselves. The following companies are implementing these strategies:

Amgen Inc. - regional expansion

BCN Peptides SA - innovation pipeline

Centrexion Therapeutics Corp - premium pricing

Daewoong Pharmaceutical Co Ltd - local manufacturing

Grunenthal GmbH - OEM tie-ups

Kyowa Hakko Kirin Co Ltd - vertical integration

Key Transient Receptor Potential Cation Channel Subfamily V Member 1 Companies15 items

Amgen Inc.

Amorepacific Corp

BCN Peptides SA

Centrexion Therapeutics Corp

Daewoong Pharmaceutical Co Ltd

DoNatur GmbH

Flex Pharma Inc.

Grunenthal GmbH

Kyowa Hakko Kirin Co Ltd

Medifron DBT Co Ltd

Neurim Pharmaceuticals Ltd

Pila Pharma AB

Sylantis SAU

Toray Industries Inc.

Vitality Biopharma Inc

Market Ecosystem

The Transient Receptor Potential Cation Channel Subfamily V Member 1 ecosystem encompasses a complex network of participants, from upstream technology providers to downstream end users. This ecosystem can be broadly segmented into three stages: upstream, midstream, and downstream, with value created and captured at each stage. The ecosystem involves various entities, including technology providers, suppliers, integrators, channels, and end users, all of which contribute to the creation and delivery of products and services related to Transient Receptor Potential Cation Channel Subfamily V Member 1.

Raw material/component suppliers — provide essential components

OEMs / manufacturers — design and manufacture products

Technology providers — develop enabling technologies

System integrators / EPCs — integrate systems and solutions

Distributors / channel partners — distribute products and services

End users / buyers — purchase and utilize products and services

Regulators/standards bodies — establish standards and regulations

In the Transient Receptor Potential Cation Channel Subfamily V Member 1 ecosystem, value flows through the various participants, with each stage influencing the next. Control points, such as regulatory approvals and standards, can significantly impact adoption. Dependency risks, including input constraints and approvals, can also affect the ecosystem. Furthermore, switching costs, partnerships, and interoperability requirements can influence the relationships between participants. As the ecosystem differs by region, with varying standards and regulations, understanding these dynamics is crucial for a comprehensive value chain analysis.

Recent Industry Insights

The Transient Receptor Potential Cation Channel Subfamily V Member 1 industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships, such as the collaboration between pharmaceutical companies to develop novel therapies targeting TRPV1, have been instrumental in driving growth. Additionally, the industry has seen notable mergers and acquisitions, with key players expanding their portfolios to include TRPV1-focused products.

Furthermore, there have been several product launches and technology advancements in the field, including the introduction of new small molecule inhibitors and biologics. Regulatory changes, such as updated guidelines for clinical trials, have also impacted the industry. These developments, coupled with a shift in consumer trends towards more targeted and personalized therapies, are expected to shape the future of the Transient Receptor Potential Cation Channel Subfamily V Member 1 industry.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Transient Receptor Potential Cation Channel Subfamily V Member 1 market. The market attractiveness is moderate, driven by increasing research activities and potential therapeutic applications. Competitive intensity is high, with several key players investing heavily in research and development. The long-term outlook for the Transient Receptor Potential Cation Channel Subfamily V Member 1 market outlook is promising, with growing demand for innovative treatments.

The innovation landscape is rapidly evolving, with advancements in gene therapy and small molecule therapeutics. However, the demand-supply balance is a concern, with limited supply of effective treatments. Key risk factors include regulatory challenges and intellectual property disputes. Overall, the market presents opportunities for growth, but careful navigation of the competitive landscape and innovation ecosystem is crucial for success.

11 items

1. Executive Summary

2. Transient Receptor Potential Cation Channel Subfamily V Member 1 Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Ophthalmology

6.1.2. Immunology

6.1.3. Muscle Spasm

6.1.4. Pruritus

6.1.5. Abdominal Pain

6.1.6. Others

6.2. Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. CMX-020

6.2.2. CA-016

6.2.3. DD-04107

6.2.4. Others

6.3. Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Market Competition by Key Manufacturers

8.1. Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Transient Receptor Potential Cation Channel Subfamily V Member 1: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Amgen Inc.

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Amorepacific Corp

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. BCN Peptides SA

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Centrexion Therapeutics Corp

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Daewoong Pharmaceutical Co Ltd

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. DoNatur GmbH

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Flex Pharma Inc.

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Grunenthal GmbH

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Kyowa Hakko Kirin Co Ltd

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Medifron DBT Co Ltd

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Neurim Pharmaceuticals Ltd

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Pila Pharma AB

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Sylantis SAU

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Toray Industries Inc.

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Vitality Biopharma Inc

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Market

Figure 4: Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Market: Drivers

Figure 5: Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Market: Challenges

Figure 6: Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Market: Trends

Figure 7: Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Market: Opportunity

Figure 8: Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Market: Restraint

Figure 9: Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Market Value (USD Million) By Region

Figure 15: Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Market Value (USD Million) By Region

Figure 23: Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

83 items

Table 1: Market Segmentation Analysis

Table 2: Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Market Value (USD Million) By Region

Table 10: Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Amgen Inc. Basic Information And Sales Area

Table 31: Amgen Inc.. Products Portfolio

Table 32: Amorepacific Corp Basic Information And Sales Area

Table 33: Amorepacific Corp. Products Portfolio

Table 34: BCN Peptides SA Basic Information And Sales Area

Table 35: BCN Peptides SA. Products Portfolio

Table 36: Centrexion Therapeutics Corp Basic Information And Sales Area

Table 37: Centrexion Therapeutics Corp. Products Portfolio

Table 38: Daewoong Pharmaceutical Co Ltd Basic Information And Sales Area

Table 39: Daewoong Pharmaceutical Co Ltd. Products Portfolio

Table 40: DoNatur GmbH Basic Information And Sales Area

Table 41: DoNatur GmbH. Products Portfolio

Table 42: Flex Pharma Inc. Basic Information And Sales Area

Table 43: Flex Pharma Inc.. Products Portfolio

Table 44: Grunenthal GmbH Basic Information And Sales Area

Table 45: Grunenthal GmbH. Products Portfolio

Table 46: Kyowa Hakko Kirin Co Ltd Basic Information And Sales Area

Table 47: Kyowa Hakko Kirin Co Ltd. Products Portfolio

Table 48: Medifron DBT Co Ltd Basic Information And Sales Area

Table 49: Medifron DBT Co Ltd. Products Portfolio

Table 50: Neurim Pharmaceuticals Ltd Basic Information And Sales Area

Table 51: Neurim Pharmaceuticals Ltd. Products Portfolio

Table 52: Pila Pharma AB Basic Information And Sales Area

Table 53: Pila Pharma AB. Products Portfolio

Table 54: Sylantis SAU Basic Information And Sales Area

Table 55: Sylantis SAU. Products Portfolio

Table 56: Toray Industries Inc. Basic Information And Sales Area

Table 57: Toray Industries Inc.. Products Portfolio

Table 58: Vitality Biopharma Inc Basic Information And Sales Area

Table 59: Vitality Biopharma Inc. Products Portfolio

Table 60: Global Market Value (USD Million) (2025-2032) By Application

Table 61: Global Market Share (%) By Application (2032)

Table 62: Global Market Value (USD Million) (2025-2032) By Types

Table 63: Global Market Share (%) By Types (2032)

Table 64: Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Market Value (USD Million) By Region

Table 65: Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Market Share (%) By Region (2025-2032)

Table 66: North America Market Value (USD Million) (2025-2032) By Country

Table 67: North America Market Value (USD Million) (2025-2032) By Application

Table 68: North America Market Value (USD Million) (2025-2032) By Types

Table 69: Europe Market Value (USD Million) (2025-2032) By Country

Table 70: Europe Market Value (USD Million) (2025-2032) By Application

Table 71: Europe Market Value (USD Million) (2025-2032) By Types

Table 72: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 73: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 74: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 75: South America Market Value (USD Million) (2025-2032) By Country

Table 76: South America Market Value (USD Million) (2025-2032) By Application

Table 77: South America Market Value (USD Million) (2025-2032) By Types

Table 78: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 79: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 80: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 81: Research Programs/Design For This Report

Table 82: Key Data Information From Secondary Sources

Table 83: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Transient Receptor Potential Cation Channel Subfamily V Member 1 Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.72 billion
Growth rate	CAGR of 15.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Amgen Inc.; Amorepacific Corp; BCN Peptides SA; Centrexion Therapeutics Corp; Daewoong Pharmaceutical Co Ltd; DoNatur GmbH; Flex Pharma Inc.; Grunenthal GmbH; Kyowa Hakko Kirin Co Ltd; Medifron DBT Co Ltd; Neurim Pharmaceuticals Ltd; Pila Pharma AB; Sylantis SAU; Toray Industries Inc.; Vitality Biopharma Inc
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options